Entero Therapeutics Grapples with Financial Strain and Compliance Issues

The latest announcement is out from Entero Therapeutics (ENTO).

Entero Therapeutics, Inc. is navigating financial turmoil after its subsidiary ImmunogenX, LLC received a Notice of Default, demanding immediate payment of all obligations which total approximately $6.99 million. Additionally, the company is facing non-compliance with Nasdaq’s audit committee requirements following the resignation of two board members. In response to these challenges, Entero has cut costs by terminating non-essential employees, vacating its office, and pausing non-essential research, while exploring various strategic alternatives to maximize stakeholder value.

For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.